• About PEGASYS + COPEGUS Combination Therapy
• The Benefits of Treatment
• PEGASYS Dosing
• Efficacy Across the Broadest Range of Patients
• Efficacy for Patients With HCV/HIV Coinfection
• Efficacy for Patients With Hepatitis B
• Safety and Tolerability
• Patient Support
• Resource Library
• Healthcare Professional Tools
• Guide to PEGASYS Prefilled Syringes

In clinical trials, PEGASYS—alone or in combination with COPEGUS^® (Ribavirin, USP)—provided predictable and reproducible sustained virologic response (SVR) rates regardless of patient type.

Sustained Virologic Response (SVR) Rates in PEGASYS + COPEGUS Trials

PEGASYS + COPEGUS combination therapy was evaluated in patients with hepatitis C monoinfection in two separate clinical trials:

• In a study conducted by Fried et al, patients were randomized to receive either PEGASYS 180 µg qw with placebo, PEGASYS 180 µg qw with COPEGUS 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg), or Rebetron^® (interferon alfa-2b 3 MIU tiw plus 1000 mg or 1200 mg ribavirin) for 48 weeks of therapy followed by 24 weeks of treatment-free follow-up.^1,2
• In a double-blind clinical trial, all patients received PEGASYS 180 µg qw and were randomized to treatment for either 24 or 48 weeks and to a COPEGUS dose of either 800 mg or 1000 mg/1200 mg (for body weight <75 kg/≥75 kg).³
• In both trials, SVR was defined as undetectable HCV RNA value at the end of the 24-week treatment-free follow-up period (week 72).^1-3

SVR Regardless of Patient Type

In two clinical trials, more than half of all patients on PEGASYS + COPEGUS combination therapy achieved an SVR. Response rates for patients with genotype 1 were 44% and 51% in the 2 studies.^1-3

Patients With High Viral Load (>800,000 IU/mL)

In two clinical studies, 53% and 59% of all patients on PEGASYS + COPEGUS combination therapy achieved an SVR. Patients with genotype 1 had an SVR rate of 41% and 47%, respectively, in the same studies.^1,3

Patients With Cirrhosis

Patients with cirrhosis at the start of combination therapy with PEGASYS + COPEGUS responded at an overall rate (for all genotypes) of 49%. Patients with genotype 1 had a 37% SVR rate.⁴

Coinfected Patients

Among all patients with both HCV and HIV on PEGASYS + COPEGUS combination therapy, 40% (116 of 289) achieved an SVR. The rate was 29% (51 of 176) among coinfected patients with HCV genotype 1.⁵

Patients With HBV Monoinfection

*<20,000 copies/mL for HBeAg-negative patients.

Patients with HBeAg-positive HBV on PEGASYS monotherapy demonstrated seroconversion in 32% of cases (87 of 271).⁶ Among patients with HBeAg-negative HBV, 43% (76 of 177) showed an HBV DNA response and 59% (105 of 177) had evidence of ALT normalization.⁷

1. Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
2. PEGASYS Prescribing Information.
3. Hadziyannis SJ et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
4. Marcellin P et al. Combination peginterferon alfa-2a (40KD) (PEGASYS^®) and ribavirin (COPEGUS^®) is efficacious and safe in patients with chronic hepatitis C and compensated cirrhosis. Presented at 38th Annual Meeting of the European Association for the Study of the Liver; July 3-6, 2003; Geneva, Switzerland.
5. Torriani FJ et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
6. Lau GKK et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2965.
7. Marcellin P et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-1217.